Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sotalol

S H Hohnloser1, R L Woosley

  • 1Department of Cardiology, University Hospital, Freiburg, Germany.

The New England Journal of Medicine
|July 7, 1994
PubMed
Summary
This summary is machine-generated.

Sotalol, an antiarrhythmic drug, effectively prevents recurrent arrhythmias like ventricular tachycardia and sudden cardiac death. It offers a unique profile compared to traditional beta-blockers, but carries a risk of torsade de pointes due to QT interval prolongation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Management of oral anticoagulation related intracerebral hemorrhage].

Herz·2019
Same author

A computerized scoring system to improve assessment of heparin-induced thrombocytopenia risk.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Anticoagulation in atrial fibrillation : Current evidence and guideline recommendations.

Herz·2017
Same author

[Implantable sensors for outpatient assessment of ventricular filling pressure in advanced heart failure : Which telemonitoring design is optimal?]

Herzschrittmachertherapie & Elektrophysiologie·2016
Same author

[Treatment safety of non-vitamin K oral anticoagulants in patients with atrial fibrillation].

Herz·2015
Same author

Medical decision support systems and therapeutics: The role of autopilots.

Clinical pharmacology and therapeutics·2015
Same journal

Sparganosis.

The New England journal of medicine·2026
Same journal

Caring for an Aging America - The Looming Crisis of the Long-Term-Care Workforce.

The New England journal of medicine·2026
Same journal

For Those Left Behind.

The New England journal of medicine·2026
Same journal

Colliding Forces - The Aging of the Baby Boom Generation and Contracting Nursing-Home Supply.

The New England journal of medicine·2026
Same journal

Mandated State-Level Surveillance of Assisted Reproductive Technology - An Emerging Threat in the United States.

The New England journal of medicine·2026
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Sotalol is a unique antiarrhythmic medication.
  • Its properties differ from standard beta-receptor antagonists.

Purpose of the Study:

  • To evaluate sotalol's efficacy and safety in treating cardiac arrhythmias.
  • To compare sotalol with other antiarrhythmic agents.

Main Methods:

  • Clinical trials assessing sotalol's effectiveness in patients with ventricular and supraventricular arrhythmias.
  • Electrophysiologic studies to understand its cardiac effects.

Main Results:

  • Sotalol demonstrates a high success rate in preventing arrhythmia recurrence, especially in ventricular tachycardia and aborted sudden cardiac death.
  • The drug exhibits a balanced hemodynamic effect, combining beta-blockade with a positive inotropic action.

Related Experiment Videos

  • Efficacy is noted in both life-threatening ventricular and supraventricular arrhythmias.

    • Conclusions:

    • Sotalol is an effective antiarrhythmic agent for various arrhythmias.
    • Its distinct electrophysiologic profile offers advantages over conventional treatments.
    • Potential adverse effects, including torsade de pointes, require careful monitoring due to QT prolongation.